A Novo Nordisk executive was brutally stabbed to death in a random attack outside a Connecticut grocery store, while his wife miraculously survived the same frenzied assault that left multiple victims.
Former President Donald Trump is reportedly pushing pharmaceutical giant Novo Nordisk for major Ozempic price cuts in a move that could transform diabetes and weight loss treatment accessibility in America.
The pharmaceutical weight loss market heats up as Novo Nordisk's blockbuster drugs Wegovy and Ozempic confront serious competition from Eli Lilly's Mounjaro, reshaping diabetes and obesity treatment landscapes.
Danish pharmaceutical giant Novo Nordisk cuts sales and profit forecasts for second time amid intensifying competition in weight-loss drug market.
The UK government launches a national security probe into major pharmaceutical investments by US-based Pfizer and Denmark's Novo Nordisk, raising concerns about foreign influence in Britain's vital healthcare sector.
Danish pharmaceutical giant Novo Nordisk enters bidding war with Pfizer for obesity biotech firm Metsera, signalling major shift in weight-loss treatment market competition.
Danish pharmaceutical giant Novo Nordisk faces major leadership shakeup as chairman and six board members step down following unprecedented growth of weight-loss drug Wegovy.
Former President Donald Trump's critical comments about weight-loss drugs like Ozempic triggered dramatic market movements, wiping billions from pharmaceutical giants before a partial recovery.
Former President Donald Trump pledges to slash prices of weight-loss drugs Ozempic and Wegovy, sending pharmaceutical stocks tumbling and sparking healthcare debate.
Governor Gavin Newsom takes unprecedented action against pharmaceutical giants as insulin prices soar, making California first US state to produce its own affordable medication.
Native American communities face critical shortages of diabetes medications like Ozempic as wealthy New Yorkers exploit prescriptions for weight loss, creating a healthcare crisis for vulnerable populations.
Pfizer announces a surprising turnaround in its weight-loss strategy, advancing two new daily pills in a heated battle for the lucrative obesity drug market dominated by injectables.
A major UK trial reveals the new semaglutide pill, a potential game-changer in obesity treatment, leads to significant weight loss, offering a powerful alternative to injections.
Danish pharmaceutical giant Novo Nordisk announces major £90 million expansion at its Gatwick facility to meet soaring global demand for its blockbuster diabetes and weight-loss drugs, Ozempic and Wegovy, creating new high-skilled jobs.
Danish pharmaceutical giant Novo Nordisk's market value skyrockets past £400bn, briefly eclipsing the entire Danish economy, on the back of soaring demand for its blockbuster weight-loss drug, Wegovy.
German authorities have confiscated thousands of doses of the in-demand weight-loss medication Wegovy from a Frankfurt wholesaler, citing illegal parallel imports from outside the EU and improper storage conditions.
Global markets reel as former President Donald Trump announces sweeping new tariffs on the EU, targeting key industries from cars to pharmaceuticals. The move sends the pound and euro tumbling and casts a shadow over Novo Nordisk's major UK investment pla
Danish pharmaceutical giant Novo Nordisk announces major restructuring, cutting 9,000 jobs globally. The move comes as competition intensifies in the lucrative weight-loss and diabetes drug market, challenging its blockbuster medications Ozempic and Wegov
Novo Nordisk has announced significant price cuts for its popular weight-loss and diabetes drugs, Ozempic and Wegovy, making them more accessible to patients across the UK.
The cost of diabetes and weight-loss drugs Mounjaro and Ozempic has surged, sparking concerns over affordability and market competition. Experts weigh in on the implications.
Sales of Novo Nordisk's blockbuster diabetes medications, including Ozempic, have dropped unexpectedly. Experts weigh in on the causes and future implications.
Novo Nordisk's blockbuster weight-loss drug Wegovy drives record sales, boosting shares and intensifying competition with Eli Lilly.
The US obesity epidemic has led to soaring demand for Wegovy, a weight-loss injection containing semaglutide. Experts warn of supply shortages as prescriptions surge.